[Federal Register Volume 85, Number 131 (Wednesday, July 8, 2020)]
[Notices]
[Page 41065]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14614]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-679]
Importer of Controlled Substances Application: Galephar
Pharmaceutical Research, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before August 7, 2020.
Such persons may also file a written request for a hearing on the
application on or before August 7, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on June 22, 2020, Galephar Pharmaceutical Research,
Inc., 100 Carr 198 Industrial Park, Juncos, Puerto Rico 00777-3873,
applied to be registered as an importer of the following basic
class(es) of a controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Hydromorphone......................... 9150 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
finished dosage form for analytical purpose only.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14614 Filed 7-7-20; 8:45 am]
BILLING CODE P